Navigation Links
aTyr Pharma Secures $23M Financing From Top Tier Venture Investor

SAN DIEGO, Oct. 26 /PRNewswire/ -- aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates.  Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.  Proceeds will be used to accelerate the development of aTyr's preclinical pipeline and advance physiocrine drug candidates into clinical trials.  Physiocrines are a recently elucidated class of endogenous human proteins that function as extracellular signaling molecules in a variety of physiologic settings.  As either therapeutic proteins or as targets for antibodies, physiocrines have the potential to address a wide range of diseases, including high unmet patient needs in blood, immune, and metabolism disorders.

"Physiocrines offer a completely new set of physiologic extracellular pathways for developing novel therapeutics.  These natural human proteins function in normal and pathologic settings, yet act via mechanisms that are differentiated and potentially superior from other therapeutic approaches," said James C. Blair, Ph.D., Partner at Domain Associates.  "We believe multiple products within aTyr's portfolio offer promise for fundamentally improved patient care while achieving attractive commercial goals.  We are enthusiastic to work with aTyr's leadership team and existing syndicate to build a world class protein therapeutics enterprise."  

"Attracting investors with a successful track record in protein therapeutics further re-enforces the therapeutic promise of our new class of human proteins, physiocrines.  As the exclusive developer of physiocrine-based therapeutics, aTyr is well positioned by this recent financing to further build a strong, sustainable pipeline of innovative medicines for patients," said Jeff Watkins, Ph.D., Chief Executive Officer of aTyr Pharma.  "Our initial physiocrine program heading to the clinic, Tmax, for treating thrombocytopenia, will serve as our first proof of concept for this exciting class of protein-based therapeutics."

As part of the financing Dr. James C. Blair will serve as a Director for the company, joining current board members Mr. John Clarke, Dr. David Mack, Dr. John Mendlein, Dr. Amir Nashat, Dr. Paul Schimmel and Dr. Jeff Watkins.

About Physiocrines

Physiocrines are a new class of extracellular proteins that modulate signaling pathways in a variety of physiological processes.  Physiocrines are derived from tRNA synthetases, which function intracellularly, and thus were overlooked by genomic discovery efforts.  These endogenous human proteins have a broad range of activities and act through a variety of receptor classes, via mechanisms distinct from current pharmaceuticals, and have applications relevant to a number of therapeutic areas ranging from immunology and hematology to metabolism disorders.

About aTyr Pharma

aTyr Pharma develops biologic therapeutics based on physiocrines, and is currently focusing on developing products to improve patient care in immune, metabolic, and hematologic indications.  aTyr Pharma has established a dominant intellectual property estate surrounding physiocrine based compositions and therapeutic applications. The company's leading program, Tmax, is in preclinical development.  The privately held biotech was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur, and John Clarke from Cardinal Partners.  aTyr Pharma is backed by leading life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information please visit

SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
4. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
5. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
6. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
7. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
8. Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug
9. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
11. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):